INOVIO VERY MUCH REMAINS IN PLAY
WHO Solidarity Trial: IN PLAY
Advaccine/China/Boosters: IN PLAY
DOD/Cellectra/Rapid Response: IN PLAY
Until all of these options are off the table, Inovio remains a live wire. We may have had delays (as frustrating as they may be), but there have been no actual trial failures. None. So don't let anyone kid you. Until we have actual trial failures, we remain on course.
WHO intent to publish: January 2023
Ebola/Lassa/MERS results: soon
Advaccine/Boosters results: soon
The upcoming week will be volatile. We have end of quarter coming Friday. This affects balancing concerns of all HFs and institutions. We also have the end of federal fiscal year. Let it all shake out as it may, and then focus on a critical upcoming quarter with many catalysts expected.
Let the FUDsters obfuscate and do their usual tap dance. It's gotten boring and predictable.
A Direct Quote From INOVIO Press Release......"INOVIO and it's collaborators pioneered the development of dMAb technology as an unique asset to not only combat the Covid-19 pandemic, but for any other pathogen or disease that can be treated by antibody therapy, including cancer"
"Empowered by more than $80 million in previous development funding from DARPA,as well as the Bill and Melinda Gates Foundation and the National Institute of Health,INOVIO's dMAb technology offers a breadth of several unique advantages across disease and pathogen targets ".....Monoclonal antibodies are a massive piece of the pharmaceutical industry with more than $100 Billion in sales and dMAb's offer a unique ability to enhance and improve these treatments....July 7th 2022 the first human dMAb trials began in conjunction with AstraZeneca and Wistar.....INOVIO ushering in a new era in medicine!!!!!